Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported on September 14 that fiscal first-quarter 2027 revenue increased 60% to $31.0 million. Gross margin reached 56.5%, up from 45.7%, for the quarter ended July 31, 2026.
Management raised fiscal 2027 revenue guidance to $141 million from $137 million, implying 48% annual growth. The outlook strengthens the commercial story, but the expanding organization still consumes substantially more than the business generates in gross profit.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) attributed revenue growth to wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories, a higher proportion of in-network patients and improvements in revenue cycle management.
These drivers suggest several ways to expand: reach more patients, improve reimbursement outcomes, and collect revenue more effectively. Their investment value depends on sustaining growth without requiring a matching increase in support costs.
Gross profit nearly doubled to $17.5 million from $8.9 million. Management attributed the margin improvement to higher volume, the in-network patient mix, and cost initiatives. The company is retaining more of each revenue dollar to fund selling expenses and product development.
#million #kestra #kmts
Management raised fiscal 2027 revenue guidance to $141 million from $137 million, implying 48% annual growth. The outlook strengthens the commercial story, but the expanding organization still consumes substantially more than the business generates in gross profit.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) attributed revenue growth to wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories, a higher proportion of in-network patients and improvements in revenue cycle management.
These drivers suggest several ways to expand: reach more patients, improve reimbursement outcomes, and collect revenue more effectively. Their investment value depends on sustaining growth without requiring a matching increase in support costs.
Gross profit nearly doubled to $17.5 million from $8.9 million. Management attributed the margin improvement to higher volume, the in-network patient mix, and cost initiatives. The company is retaining more of each revenue dollar to fund selling expenses and product development.
#million #kestra #kmts
2 months ago
